These findings revealed the regulatory role of ZFP36/GBP2/YAP1/TEAD1 signaling in VSMC phenotypic switch and AAA formation, and provided a novel strategy (Dex) for AAA treatment. The gene discussed is GBP2; the disease is triple-A syndrome.